Prostate-specific membrane antigen (PSMA) gene expression predicts angiogenesis and response to tyrosine kinase inhibitors (TKIs) in patients with metastatic clear cell renal cell carcinoma (RCC), ...

Taletrectinib can be effective in patients with TKI-naïve or TKI-pretreated advanced NSCLC, a pooled analysis suggests.

After spending years tracing the origin and migration pattern of an unusual type of immune cell in mice, researchers have ...

Roivant Sciences secures $5.2B for advancing late-stage drugs like IMVT-1402 & brepocitinib. Click here to read an analysis ...

Tyrosine kinase inhibitors, such as gefitinib (Iressa ... Recent research has focused on the development of drugs that can block the tyrosine kinase oncogene by blocking EGF from binding ...

Patients were in their early 50s on average, and some 80% were women. Nearly all were white (most participants were from Eastern Europe and Chile). Mean disease duration was about 8 years. DAS28-CRP ...

The trial will focus on subjects with difficult-to-treat rheumatoid arthritis. Credit: Chinnapong / Shutterstock. The European Medicines Agency (EMA) has approved Cullinan Therapeutics’ clinical trial ...

Higher BMI did not raise cardiovascular risk in ACPA-negative patients, and appeared strongly protective in these patients using biologic drugs. Rheumatoid arthritis (RA) patients face very ...

In addition, Nurix continues to make significant progress with our pipeline of degrader-based drugs for the treatment ... in the treatment of rheumatoid arthritis and other inflammatory diseases.

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood ...

The authors explained that while molecularly targeted therapies like Bruton tyrosine kinase (BTK) inhibitors and B-cell leukemia/lymphoma-2 (BCL-2) inhibitors can target aberrant signaling ...